Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a new class of highly efficacious medications called nutrient-stimulating hormone (NuSH) therapies has emerged. This article highlights the effectiveness of the FDA-approved NuSH-based therapies-liraglutide, semaglutide, and tirzepatide-in long-term weight management. Ongoing trials are exploring novel mechanisms of action to simultaneously target multiple receptors involved in appetite and energy regulation, promising further advancements and additional treatment options in the field of obesity management.
Authors
Cristancho, Cagney; Kim, Dong Wook; Apovian, Caroline M
Keywords
NuSH-based therapiesNutrient stimulating hormonesObesitySemaglutideTirzepatideWeight loss therapies